个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Comparative analysis of dosimetric and radiobiological models of IPSA and HIPO algorithms in combined intra-cavitary/interstitial brachytherapy for cervical cancer

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yan Chuanjun[1] * ; Wang Xianliang[2] ; Wen Aiping[3] ; Luo Jingyue[2] ; Zhang Siyu[3] ; Wang Pei[2] ; Li Jie[1,2,*1] ;
机构： [1]School of Medicine, Southwest Medical University of China, Luzhou, Sichuan Province, China. [2]Department of Radiotherapy, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. [3]School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.
出处：
DOI： 10.5114/jcb.2023.128894
ISSN：

关键词： cervical cancer intra-cavitary/interstitial brachytherapy IPSA HIPO EUBED TCP/NTCP

摘要：
To compare inverse planning simulated annealing (IPSA) and hybrid inverse planning optimization (HIPO) using dosimetric and radiobiological models, and provide a basis for selecting the optimization method for cervical cancer.This was a retrospective study including 32 patients with radical cervical cancer. Brachytherapy treatment plans were re-optimized using IPSA, HIPO1 (with a locked uterine tube), and HIPO2 (with an unlocked uterine tube). Dosimetric data, including isodose lines, HR-CTV (D100, V150%, V200%, HI, and CI), and (bladder, rectum, and intestines) D1cc, D2cc for organs at risk (OARs) were also collected. Additionally, TCP, NTCP, BED, and EUBED were calculated, and differences were analyzed using matched samples t-test and Friedman test.Compared with IPSA and HIPO2, HIPO1 had better V150% and V200% (p < 0.05). Compared with IPSA and HIPO1, HIPO2 had better D100 and CI (p < 0.05). The doses to the bladder D1cc (4.72 ±0.33 Gy)/D2cc (4.47 ±0.29 Gy) and rectum D1cc (4.50 ±0.61 Gy)/D2cc (4.11 ±0.63 Gy) were lower in HIPO2 than in IPSA and HIPO1. EUBEDs for HR-CTV were higher in HIPO1 and HIPO2 than in IPSA by 1.39-1.63%. However, TCPs were not remarkably different among the three plans (p > 0.05). Also, the NTCP for the bladder was lower in HIPO2 than in IPSA and HIPO1 by 13.04% and 16.67%, respectively.Although the dosimetric parameters of IPSA, HIPO1, and HIPO2 are comparable, HIPO2 provides better dose conformability and lower NTCP. Therefore, HIPO2 is recommended as an optimization algorithm in IC/ISBT for cervical cancer.Copyright © 2023 Termedia.

基金：
This study was in part funded by a research grant (No.: 2021-DF-016) of Elekta AB (Stockholm, Sweden). The funders had no role in study design, data collection, and analysis, and decisions on preparation of the manuscript. This study was partially supported by Sichuan Science and Technology Program (No.: 2022YFG0194, 2022YFS0047, 2021YFG0320, 2020YJ0446) and Medical Engineering Innovation Fund for Cancer (No. ZYGX- 2021YGCX002).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 核医学
最新[2023]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 核医学
JCR分区：
出版当年[2023]版：
Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q4 ONCOLOGY
最新[2023]版：
Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q4 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]School of Medicine, Southwest Medical University of China, Luzhou, Sichuan Province, China.
通讯作者：
通讯机构： [1]School of Medicine, Southwest Medical University of China, Luzhou, Sichuan Province, China. [2]Department of Radiotherapy, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. [*1]School of Medicine, Southwest Medical University of China, Department of Radiotherapy, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, 4th Section, Renmin South Road, Chengdu, Sichuan Province, 610041, China
推荐引用方式(GB/T 7714)：
Yan Chuanjun,Wang Xianliang,Wen Aiping,et al.Comparative analysis of dosimetric and radiobiological models of IPSA and HIPO algorithms in combined intra-cavitary/interstitial brachytherapy for cervical cancer[J].JOURNAL OF CONTEMPORARY BRACHYTHERAPY.2023,15(3):212-219.doi:10.5114/jcb.2023.128894.
APA：
Yan Chuanjun,Wang Xianliang,Wen Aiping,Luo Jingyue,Zhang Siyu...&Li Jie.(2023).Comparative analysis of dosimetric and radiobiological models of IPSA and HIPO algorithms in combined intra-cavitary/interstitial brachytherapy for cervical cancer.JOURNAL OF CONTEMPORARY BRACHYTHERAPY,15,(3)
MLA：
Yan Chuanjun,et al."Comparative analysis of dosimetric and radiobiological models of IPSA and HIPO algorithms in combined intra-cavitary/interstitial brachytherapy for cervical cancer".JOURNAL OF CONTEMPORARY BRACHYTHERAPY 15..3(2023):212-219

相关文献

[1]Comparative analysis of dosimetric and radiobiological models of IPSA and HIPO algorithms in combined intra-cavitary/interstitial brachytherapy for cervical cancer [2]Distribution of circulating tumor cell phenotype in early cervical cancer [3]Compartmentalized activities of HMGCS1 control cervical cancer radiosensitivity [4]Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer [5]Induction Chemotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer [6]Worldwide trends in cervical cancer incidence and mortality. [7]Genomic imprinting biomarkers for cervical cancer risk stratification [8]Treatment Paradigm for Cervical Esophageal Cancer: Now and Then [9]Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer [10]Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号